Analysts’ Weekly Ratings Changes for GeneDx (WGS)

Several analysts have recently updated their ratings and price targets for GeneDx (NASDAQ: WGS):

• 5/15/2026 – GeneDx was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/9/2026 – GeneDx was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/5/2026 – GeneDx had its “buy” rating reaffirmed by Craig Hallum. They now have a $85.00 price target on the stock.
• 5/5/2026 – GeneDx was given a new $75.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 5/5/2026 – GeneDx had its “overweight” rating reaffirmed by Wells Fargo & Company. They now have a $75.00 price target on the stock, down from $155.00.
• 5/5/2026 – GeneDx had its price target lowered by Guggenheim from $100.00 to $70.00. They now have a “buy” rating on the stock.
• 5/5/2026 – GeneDx had its price target lowered by BTIG Research from $170.00 to $90.00. They now have a “buy” rating on the stock.
• 4/24/2026 – GeneDx was downgraded by Zacks Research from “strong-buy” to “hold”.
• 4/20/2026 – GeneDx was given a new $100.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 3/30/2026 – GeneDx had its price target lowered by Guggenheim from $170.00 to $100.00. They now have a “buy” rating on the stock.

Insider Activity at GeneDx

In other GeneDx news, Director Casdin Capital, Llc acquired 140,000 shares of GeneDx stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $43.81 per share, with a total value of $6,133,400.00. Following the purchase, the director owned 3,507,164 shares in the company, valued at approximately $153,648,854.84. This trade represents a 4.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Keith A. Meister acquired 46,273 shares of GeneDx stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $38.91 per share, with a total value of $1,800,482.43. Following the purchase, the director owned 4,784,570 shares in the company, valued at $186,167,618.70. The trade was a 0.98% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 2,225,941 shares of company stock valued at $95,494,951 and sold 104,028 shares valued at $7,377,165. 29.60% of the stock is owned by company insiders.

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.